Tempest Therapeutics (NASDAQ:TPST) Announces Quarterly Earnings Results

Tempest Therapeutics (NASDAQ:TPST) posted its quarterly earnings data on Wednesday. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.27) by $2.48, Zacks reports.

Tempest Therapeutics Trading Down 0.2%

NASDAQ TPST traded down $0.02 on Friday, hitting $9.52. 31,133 shares of the company were exchanged, compared to its average volume of 82,003. Tempest Therapeutics has a 12 month low of $5.33 and a 12 month high of $15.08. The company has a market cap of $42.27 million, a PE ratio of -0.95 and a beta of -2.20. The stock has a fifty day moving average of $10.34 and a 200-day moving average of $8.43.

Institutional Trading of Tempest Therapeutics

A hedge fund recently raised its stake in Tempest Therapeutics stock. Vanguard Group Inc. lifted its position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 162,560 shares of the company’s stock after purchasing an additional 27,952 shares during the quarter. Vanguard Group Inc. owned 3.66% of Tempest Therapeutics worth $1,671,000 at the end of the most recent reporting period. 22.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TPST has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Tempest Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Tempest Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $30.00.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.